Trial | NCT03007576  Report issue

Title

Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem)
Phase I Clinical Trial - Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem)

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    12
Osteoarthritis (OA) is a common and incurable disease for the elderly in Taiwan, so it is an important mission to develop a new treatment for OA. Recently, cellular therapy is a new and popular medical treatment around the world, one of them is "Mesenchymal Stromal Cells (MSCs)". MSCs are found in many tissues of human body and play an important role for repairing, regeneration, anti-inflammatory and chondrogenesis. So, MSC product, RegStem, for osteoarthritis treatment becomes a developing target for new generation drugs.

This study is to isolate and expand MSCs(RegStem) from infrapatellar fat pad of subject. When the number of MSCs expands to 1×10^8, cell will be cryopreserved in the liquid nitrogen tank until all release tests passed. On the distribution day, cell will be thawed and injected into joint cavity of patient (5×10^7). Subjects will be monitored after MSC product infusion of seven days, one month, six months and one year. The monitoring items include the changes of knee (by appearance, X-ray and MRI of knee) and pain improvement (by questionnaire).
Study Started
Aug 01
2017
Primary Completion
Aug 31
2019
Study Completion
Aug 31
2019
Last Update
Nov 13
2019

Biological RegStem

RegStem, 1.5 ml, one injection

  • Other names: MSC

RegStem Experimental

Autologous MSC, 5×10^7 cells, one injection

Criteria 

Inclusion Criteria:

Subjects who understand and sign the informed consent form for this study
Grade 2~3 osteoarthritis according to the Kellgren-Lawrence grading scale with one-month X-ray
Age is 50~75 years old
Postmenopausal women
VAS scores in 50 to 90 mm

Exclusion Criteria:

Abnormal of liver and kidney: GOT and GPT > 100 IU/L, BUN >22 mg/dl and creatinine > 1.2 mg/dl.
Positive serology for HIV, HTLV-1/2 and syphilis
Women who are pregnant or breast feeding
Serious pre-existing medical conditions: coagulation disorders, cardiovascular diseases (arrhythmias, myocardial infarction and surgery), renal diseases (chronic renal failure), liver diseases (cirrhosis), diabetes mellitus type I, cancer history.
Other joint diseases: knee deformity (knee varus greater than 10 degree or valgus greater than 20 degree), rheumatic arthritis, gouty arthritis, septic arthritis, serious meniscal tear, other autoimmune arthritis.
Skin inflammatory of knee
Knee pain caused by referred pain from spine disease or hip joint disease. Knee pain combined with pain from spine disease or hip disease.
Immunosuppressive state
Subjects who were injected with hyaluronic acid and PRP in the past 6 months
Body mass index (BMI) greater than 30
Have a history of allergic reaction of any medication
Participation in another clinical trial or treatment within 3 months
Other pathologic conditions or circumstances that difficult participation in this study according to PI's evaluations
No Results Posted